Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients.
Rhinology
; 62(4): 457-465, 2024 Aug 01.
Article
en En
| MEDLINE
| ID: mdl-38530204
ABSTRACT
BACKGROUND:
The introduction of CFTR modulators has changed the landscape in the treatment of cystic fibrosis (CF) and early case series have shown improvements in sinonasal outcomes in this patient population.METHODOLOGY:
A real-word data study was performed to evaluate the impact of dual therapy with tezacaftor/ivacaftor (TEZ/IVA) and triple therapy with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on CF-related chronic rhinosinusitis (CRS), by comparing subjective and objective outcome measures at baseline, 12 months after treatment with TEZ/IVA and six months after treatment with ELX/TEZ/IVA.RESULTS:
In total, 43 CF patients, with a mean age of 32 years, were included. After triple therapy, significant improvements in overall visual analogue scale, SNOT-22, Lund Kennedy, nasal polyps, and Lund-Mackay scores were observed, whereas no beneficial effect could be seen in patients treated with dual therapy. Bacterial upper airway colonization did not differ pre- and postmodulator therapy in the present study. The number of responders to dual and triple therapy is 23.8% and 63.2% of the patients, respectively.CONCLUSIONS:
Triple therapy with ELX/TEZ/IVA is superior to dual therapy with TEZ/IVA in the treatment of CF-CRS, as significantly reduced sinonasal complaints, nasal endoscopy and CT scores were observed after triple therapy, whereas this was not the case for dual therapy.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Sinusitis
/
Rinitis
/
Quinolonas
/
Fibrosis Quística
/
Aminofenoles
/
Indoles
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Rhinology
/
Rhinology (Leiden)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Bélgica